PMID- 34150542
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2222-3959 (Print)
IS  - 2227-4898 (Electronic)
IS  - 2222-3959 (Linking)
VI  - 14
IP  - 6
DP  - 2021
TI  - Triamcinolone as an adjunct to the combination of anti-VEGF for the management of 
      diabetic macular edema.
PG  - 869-874
LID - 10.18240/ijo.2021.06.12 [doi]
AB  - AIM: To assess the efficacy of intravitreal triamcinolone (IVTA) as an adjunct to 
      the combination of anti-vascular endothelial growth factor (VEGF) for the 
      management of diabetic macular edema (DME). METHODS: A total of 51 patients with 
      visual disabilities causing by DME from two sites were retrospectively collected 
      and assigned to two groups according to the therapeutic method: intravitreal 
      conbercept (IVC) combined with focal laser (24 eyes) and IVC combined with focal 
      laser and IVTA (27 eyes). Best-corrected visual acuity (BCVA), the required 
      number of IVCs, central retinal thickness (CRT), the mean costs of treatment 
      burden and safety were compared over 12mo. RESULTS: From baseline to month 1 
      through month 12, IVC combined with focal laser and IVTA improved the mean 
      average change in BCVA superior to IVC combined with focal laser (+5.20 vs +2.71 
      letters). At month 12, 20.83% of the IVC combined with focal laser and 37.04% of 
      IVC combined with focal laser and IVTA arms gained more than 10 BCVA letters. 
      During the period, the mean CRT decreased significantly in the IVC combined with 
      focal laser and IVTA arm (-245.9 microm) compared to the IVC combined with focal 
      laser arm (-98.45 microm). The average of 6.45 and 1.25 conbercept injections 
      performed in the IVC combined with focal laser and IVC combined with focal laser 
      and IVTA arms, respectively. The mean cost of treatment burden for 12mo was 
      $6247.44+/-4069.18 in the IVC combined with focal laser arm and $1679.19+/-542.73 in 
      the IVC combined with focal laser and IVTA arm, with a statistically significant 
      difference. Apart from occasional minor subconjunctival hemorrhage, no other 
      significant ocular adverse events (AEs) were observed in either group during 
      the12-month period. CONCLUSION: It is effective and cost-effective to treat DME 
      by utilizing triamcinolone as an adjunct to the combination of anti-VEGF.
CI  - International Journal of Ophthalmology Press.
FAU - Yu, Ying-Ying
AU  - Yu YY
AD  - Department of Ophthalmology, Peking University People's Hospital, Eye diseases 
      and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, College of Optometry, Peking University Health 
      Science Center, Beijing 100044, China.
FAU - Cheng, Yong
AU  - Cheng Y
AD  - Department of Ophthalmology, Peking University People's Hospital, Eye diseases 
      and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, College of Optometry, Peking University Health 
      Science Center, Beijing 100044, China.
FAU - Chang, Li-Bin
AU  - Chang LB
AD  - Department of Ophthalmology, Beijing Jingmei Group General Hospital, Beijing 
      102300, China.
FAU - Xia, Hui-Ka
AU  - Xia HK
AD  - Department of Ophthalmology, Peking University People's Hospital, Eye diseases 
      and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, College of Optometry, Peking University Health 
      Science Center, Beijing 100044, China.
AD  - Department of Ophthalmology, Hebei General Hospital, Shijiazhuang 050051, Hebei 
      Province, China.
FAU - Li, Xiao-Xin
AU  - Li XX
AD  - Department of Ophthalmology, Peking University People's Hospital, Eye diseases 
      and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, College of Optometry, Peking University Health 
      Science Center, Beijing 100044, China.
AD  - Xiamen Eye Center of Xiamen University, Xiamen 361003, Fujian Province, China.
LA  - eng
PT  - Journal Article
DEP - 20210618
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC8165624
OTO - NOTNLM
OT  - anti-vascular endothelial growth factor
OT  - diabetic macular edema
OT  - intravitreal triamcinolone
EDAT- 2021/06/22 06:00
MHDA- 2021/06/22 06:01
PMCR- 2021/06/18
CRDT- 2021/06/21 05:59
PHST- 2020/09/02 00:00 [received]
PHST- 2021/03/25 00:00 [accepted]
PHST- 2021/06/21 05:59 [entrez]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/06/22 06:01 [medline]
PHST- 2021/06/18 00:00 [pmc-release]
AID - ijo-14-06-869 [pii]
AID - 10.18240/ijo.2021.06.12 [doi]
PST - epublish
SO  - Int J Ophthalmol. 2021 Jun 18;14(6):869-874. doi: 10.18240/ijo.2021.06.12. 
      eCollection 2021.